pirfenidone
Selected indexed studies
- Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. (Eur Respir Rev, 2017) [PMID:29212837]
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. (Lancet, 2011) [PMID:21571362]
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (BMC Pulm Med, 2021) [PMID:34895203]
_Worker-drafted node — pending editorial review._
Connections
pirfenidone is a side effect of
Sources
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (2021) pubmed
- Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. (2024) pubmed
- Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. (2017) pubmed
- Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. (2024) pubmed
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. (2011) pubmed
- Pirfenidone as a novel cardiac protective treatment. (2022) pubmed
- Pirfenidone: A Promising Drug in Ocular Therapeutics. (2024) pubmed
- Pirfenidone use in fibrotic diseases: What do we know so far? (2024) pubmed
- Pirfenidone in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. (2022) pubmed
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. (2020) pubmed